Nrf2-regulated phase-II detoxification enzymes and phase-III transporters are induced by thyroid hormone in rat liver

BioFactors

Volumn 39, Issue 5, 2013, Pages 514-521

  Cornejo, Pamela ^a   Vargas, Romina ^b   Videla, Luis A ^b  

^a UNIVERSIDAD DIEGO PORTALES   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Liver Nrf2; Phase II detoxification enzymes; Phase III transporters; Thyroid hormone

Indexed keywords

EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 1; GLUTATHIONE S TRANSFERASE YA; GLUTATHIONE S TRANSFERASE YP; GLUTATHIONE TRANSFERASE; LIOTHYRONINE; LIVER ENZYME; LIVER PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA BINDING; DRUG TRANSPORT; GEL MOBILITY SHIFT ASSAY; HORMONAL THERAPY; HORMONE ACTION; HYPOTHESIS; IN VIVO STUDY; LIVER; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETOXIFICATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RECTUM TEMPERATURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; THERMOGENESIS; UPREGULATION; WESTERN BLOTTING;

LIVER NRF2; PHASE-II DETOXIFICATION ENZYMES; PHASE-III TRANSPORTERS; THYROID HORMONE;

ANIMALS; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INDUCTION; GLUTATHIONE TRANSFERASE; LIVER; MALE; METABOLIC DETOXICATION, PHASE II; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TRIIODOTHYRONINE;

EID: 84886428586     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1094     Document Type: Article

References (48)

1. Davis, P. J. andDavis, F. B. (1996)Nongenomic actions of thyroid hormone.Thyroid6, 497-504.
2. Cheng, S., Leonard, J. L., andDavis, P. J. (2010)Molecular aspects of thyroid hormone actions.Endocr. Rev.31, 139-170.
3. Fernández, V. andVidela, L. A. (1993)Influence of hyperthyroidism on superoxide radical and hydrogen peroxide production by rat liver submitochondrial particles.Free Radic. Res. Commun.18, 329-335.
4. Tapia, G., Pepper, I., Smok, G., andVidela, L. A. (1997)Kupffer cell function in thyroid hormone-induced liver oxidative stress.Free Radic. Res.26, 267-279.
5. Videla, L. A. (2010)Hormetic responses of thyroid hormone calorigenesis in the liver: association with oxidative stress.IUBMB Life62, 460-466.
6. Venditti, P. andDi Meo, S. (2006)Thyroid hormone-induced oxidative stress.Cell. Mol. Life Sci.63, 414-432.
7. Videla, L. A., Sir, T., andWolff, C. (1988)Increased lipid peroxidation in hyperthyroid patients: suppression by propylthiouracil treatment.Free Radic. Res. Commun.5, 1-10.
8. Aslan, M., Cosar, N., Celik, H., Aksoy, N., Dulger, A. C., et al. (2011)Evaluation of oxidative status in patients with hyperthyroidism.Endocrine40, 285-289.
9. Videla, L. A. (2010)Cytoprotective and suicidal signaling in oxidative stress.Biol. Res.43, 363-369.
10. Romanque, R., Cornejo, P., Valdés, S., andVidela, L. A. (2011)Thyroid hormone administration induces rat liver Nrf2 activation: suppression by N-acetylcysteine pretreatment.Thyroid21, 655-662.
11. Brigelius-Flohé, R. andFlohé, L. (2011)Basic principles and emerging concepts in the redox control of transcription factors.Antioxid. Redox Signal.15, 2335-2381.
12. Nguyen, T., Nioi, P., andPickett, C. (2009)The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress.J. Biol. Chem.284, 13291-13295.
13. Huang, H. C., Nguyen, T., andPickett, C. B. (2002)Phosphorylation of Nrf2 at Ser40 by protein kinase C regulates antioxidant response element-mediated transcription.J. Biol. Chem.277, 42769-42774.
14. Zhang, D. D. (2006)Mechanistic studies of the Nrf2-Keap1 signaling pathway.Drug Metab. Rev.38, 769-789.
15. Videla, L. A., Cornejo, P., Castillo, I., andRomanque, P. (2012) Thyroid hormone-induced regulatory interrelations in rat liver Nrf2-Keap1 signaling related to antioxidant enzyme expression. InAdvances in Medicine and Biology vol.55 ( Berhardt, L. B., ed.), Nova Science Publishers, New York, pp179-191.
16. Copple, I. M., Goldring, C. E., Kitteringham, N. R., andPark, B. K. (2008)The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity.Toxicology246, 24-33.
17. Shen, G. andKong, A. N. (2009)Nrf2 plays an important role in coordinated regulation of phase II drug metabolize enzymes and phase III drug transporters.Biopharm. Drug Dispos.30, 345-355.
18. Niture, S., Kaspar, J., Shen, J., andJaiswal, A. (2010)Nrf2 signaling and cell survival.Toxicol. Appl. Pharmacol.244, 37-42.
19. Klaassen, C. D. andReisman, S. (2010)Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver.Toxicol. Appl. Pharmacol.244, 57-65.
20. Deryckere, F. andGannon, F. (1994)A One-hour minipreparation technique for extraction of DNA-Binding proteins from animal tissues.Biotechniques16, 405.
21. Bradford, M. (1976)A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding.Anal. Biochem.72, 248-254.
22. Gong, P. andCederbaum, A. I. (2006)Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1.Hepatology43, 144-153.
23. Laemmli, U. K. (1970)Cleavage of structural proteins during assembly of the head of bacteriophage T4.Nature227, 680-685.
24. Towbin, H., Staehelin, T., andGordon, J. (1979)Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proc. Natl. Acad. Sci. USA76, 4350-4354.
25. Lee, O. K., Jain, A. K., Papusha, V., andJaiswal, A. K. (2007)An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance.J. Biol. Chem.282, 36412-36420.
26. Parkinson, A. (1996) Biotransformation of xenobiotics. InCasarett and Doull's Toxicology, 5th edn. ( Klaassen, C. D., ed.). pp.113-186, McGraw-Hill, New York, Chapter 6.
27. Decker, M., Arand, M., andCronin, A. (2009)Mammalian epoxide hydrolases in xenobiotic metabolism and signaling.Arch. Toxicol.83, 297-318.
28. Fernández, V. andVidela, L. A. (1989) Thyroid hormone, active oxygen, and lipid peroxidation, InHandbook of Free Radicals and Antioxidants in Biomedicine ( Miquel, J., Quintanilha, A. T., and Weber, H., eds.). pp.105-115, CRC Press, Boca Raton, Florida, Vol.1.
29. Park, E. J., Min, H., Park, H., Chung, H., Ahn, Y., et al. (2011)Nuclear factor E2-related factor-mediated induction of NAD(P) H: quinone oxidoreductase 1 by 3, 5-dimethoxy-trans-stilbene.J. Pharmacol. Sci.116, 89-96.
30. Potts-Kant, E. N., Li, Z., Tighe, R. M., Lindsey, J. Y., Frush, B. W., et al. (2012)NAD(P)H:quinone oxidoreductase 1 protects lungs from oxidant-induced emphysema in mice.Free Radic. Biol. Med.52, 705-715.
31. Corley, R. A., English, J. C., Hill, T. S., Fiorica, L. A., andMorgott, D. A. (2000)Development of a physiologically based pharmacokinetic model for hydroquinone.Toxicol. Appl. Pharmacol.165, 163-174.
32. O, Connor, P. andFeely, J. (1987)Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.Clin. Pharmacokinet.13, 345-364.
33. Scott, A. K., Khir, A. S., Bewsher, P. D., andHawksworth, G. M. (1984)Oxazepam pharmacokinetics in thyroid disease.Br. J. Clin. Pharmacol.17, 49-53.
34. , -triiodothyronine sulfate: studies in thyroidal and non-thyroidal diseases, pregnancy, and neonatal life.J. Clin. Endocrinol. Metab.75, 189-194.
35. Maher, J. M., Dieter, M. Z., Aleksunes, L. M., Slitt, A. L., Guo, G., et al. (2007)Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway.Hepatology46, 1597-1610.
36. Xu, C., Li, C. Y., andKong, A. N. (2005)Induction of phase I, II and III drug metabolism/transport by xenobiotics.Arch. Pharm. Res.28, 249-268.
37. Klaassen, C. D. andLu, H. (2008)Xenobiotic transporters: ascribing function from gene knockout and mutation studies.Toxicol. Sci.101, 186-196.
38. Pang, K. S., Maeng, H. J., andFan, J. (2009)Interplay of transporters and enzymes in drug and metabolite processing.Mol. Pharmac.6, 1734-1755.
39. Borst, P., de Wolf, C., andvan de Watering, K. (2007)Multidrug resistance associated proteins 3, 4, and 5.Pfluegers Arch.453, 661-673.
40. Belinsky, M. G., Dawson, P. A., Shchaveleva, I., Bain, L. J., Wang, R., et al. (2005)Analysis of the in vivo functions of Mrp3.Mol. Pharmacol.68, 160-168.
41. Nies, A. T., Schwab, M., andKeppler, D. (2008)Interplay of conjugating enzymes with Oatp uptake transporters and Abc/Mrp efflux pumps in the elimination of drugs.Expert Opin. Drug Metab. Toxicol.4, 545-568.
42. Lecureux, L., Dieter, M. Z., Nelson, D. M., Watson, L., Wong, G., et al. (2009)Hepatobiliary disposition of thyroid hormone in Mrp2-deficient TR-rats: reduced biliary excretion of thyroxine glucuronide does not prevent xenobiotic-induced hypothyroidism.Toxicol. Sci.108, 482-491.
43. Kurose, K., Mayumi, S., Tohkin, M., andHasegawa, R. (2008)Thyroid hormone receptor mediates human MDR1 gene expression. Identification of the response region essential for gene expression.Arch. Biochem. Biophys.474, 82-90.
44. Jin, M., Shimada, T., Shintani, M., Yokogawa, K., Nomura, M., et al. (2005)Long-term levothyroxine treatment decreases the oral bioavailability of ciclosporin A by inducing P-glycoprotein in small intestine.Drug Metab. Pharmacokinet.20, 324-330.
45. Nishio, N., Katsura, T., Ashida, K., Okuda, M., andInui, K. (2005)Modulation of P-glycoprotein expression in hyperthyroid rat tissues.Drug Metab. Dispos.33, 1584-1587.
46. Siegmund, W., Altmannsberger, S., Paneitz, A., Hecker, U., Zschiesche, M., et al (2002)Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition.Clin. Pharmacol. Ther.72, 256-264.
47. Cetinkalp, S., Karadeniz, M., Erdogan, M., Eroglu, Z., Zengi, A., et al. (2010)Human multidrug resistance-1 gene expression levels in Graves-Basedow disease.Exp. Clin. Endocrinol. Diabet.118, 158-160.
48. Vessel, E. S., Shapiro, J. R., Passananti, T., Jorgensen, H., andShively, C. A. (1975)Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.Clin. Pharmacol. Ther.17, 48-56.